BIOMAT Database Logo BIOMAT Database Logo

Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization. 2015

Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Starting from our previously identified novel c-Met kinase inhibitors bearing 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one scaffold, a global structural exploration was conducted to furnish an optimal binding motif for further development, directed by the enzyme inhibitory mechanism. First round SAR study picked two imidazonaphthyridinone frameworks with 1,8- and 3,5-disubstitution pattern as class I and class II c-Met kinase inhibitors, respectively. Further structural optimization on type II inhibitors by truncation of the imidazonaphthyridinone core and incorporation of an N-phenyl cyclopropane-1,1-dicarboxamide pharmacophore led to the discovery of novel imidazopyridine-based c-Met kinase inhibitors, displaying nanomolar enzyme inhibitory activity and improved Met kinase selectivity. More significantly, the new chemotype c-Met kinase inhibitors effectively inhibited Met phosphorylation and its downstream signaling as well as the proliferation of Met-dependent EBC-1 human lung cancer cells at submicromolar concentrations.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017434 Protein Structure, Tertiary The level of protein structure in which combinations of secondary protein structures (ALPHA HELICES; BETA SHEETS; loop regions, and AMINO ACID MOTIFS) pack together to form folded shapes. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Tertiary Protein Structure,Protein Structures, Tertiary,Tertiary Protein Structures
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
June 2012, ChemMedChem,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase.
November 2013, Bioorganic & medicinal chemistry letters,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
Discovery of 1H-Imidazo[4,5-b]pyridine Derivatives as Potent and Selective BET Inhibitors for the Management of Neuropathic Pain.
July 2023, Journal of medicinal chemistry,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor.
June 2016, Bioorganic & medicinal chemistry letters,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities.
June 2023, Journal of medicinal chemistry,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
September 2016, Bioorganic & medicinal chemistry,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors.
August 2010, Bioorganic & medicinal chemistry letters,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
[Imidazo-(4,5-B)-pyridine].
November 1970, Bollettino chimico farmaceutico,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.
March 2013, Organic & biomolecular chemistry,
Xiao-De An, and Hongyan Liu, and Zhong-Liang Xu, and Yi Jin, and Xia Peng, and Ying-Ming Yao, and Meiyu Geng, and Ya-Qiu Long
Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives.
March 2017, Molecules (Basel, Switzerland),
Copied contents to your clipboard!